Clinical Trial Update: MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating durvalumab (MEDI4736) in combination with selumetinib for KRAS-mutant non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MEDI4736 (Durvalumab)
• Selumetinib (selumetinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Advanced Lung Cancer | Phase 2 | Status: WITHDRAWN